Crisil Ratings reports that President Trump's order to cut US drug prices will have a limited effect on Indian pharma.

The prefilled syringe drug molecule market has seen significant evolution as healthcare systems globally strive for safer, more efficient drug delivery methods. Prefilled syringes offer an innovative ...

I've always wanted to differentiate; I never wanted to be a me-too. I always want to lead, not follow,' says Executive ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.

Abbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. Foreign exchange remains ...

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands ...

It’s no secret that prescription drugs can take a toll on your wallet. One classification of medication in particular—biologics—has had an oversized impact on the rising cost of prescription drugs.